Diabetes

Your daily dose of the clinical news you may have missed.

New data to be presented at ECO 2025 shows new-onset T2D is linked to increased risk of liver, pancreatic, and bowel cancers, but not endometrial or post-menopausal breast cancer.

Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.

The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%

Breaking research presented at ACP Internal Medicine 2025 showed that switching GLP1-RAs resulted in better glucose and weight control among adults with inadequately controlled T2D.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Your daily dose of the clinical news you may have missed.

Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

The 30-year program has tracked and compiled data on diabetes prevention, treatment, and outcomes, providing a foundation and insights for international research.

A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.

Your daily dose of the clinical news you may have missed.

Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

Your daily dose of the clinical news you may have missed.

CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from a pilot study in T2D.

Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.

Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.

Panelists discuss how patient selection for teplizumab therapy requires screening for specific autoantibodies and stages of Type 1 diabetes, followed by a standardized 14-day outpatient infusion protocol with careful monitoring for side effects.

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

Panelists discuss how islet autoantibody testing serves as a critical screening tool for identifying Type 1 diabetes risk, with tests detecting antibodies against insulin, GAD65, IA-2, and ZnT8 proteins being the most clinically validated markers.

Panelists discuss how patient selection for teplizumab therapy requires careful screening for autoantibody positivity and preserved C-peptide function, followed by a 14-day outpatient infusion process that needs close monitoring for cytokine release syndrome and other potential adverse effects.

Panelists discuss how teplizumab demonstrated efficacy in clinical trials by delaying type 1 diabetes onset in high-risk patients.

Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.